Morgan Stanley Maintains Overweight on ShockWave Medical, Lowers Price Target to $313
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Patrick Wood has maintained an Overweight rating on ShockWave Medical (NASDAQ:SWAV) but lowered the price target from $335 to $313.
August 10, 2023 | 2:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has maintained an Overweight rating on ShockWave Medical but lowered the price target from $335 to $313.
The news is directly about ShockWave Medical. While the Overweight rating is maintained, indicating a positive outlook, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100